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Background:  Prevalence  of the  hepatitis  C virus  (HCV)  among  people  who  inject  drugs  (PWID)  in  Scotland
is  high.  The  Scottish  Government  has  invested  signiﬁcantly  in harm  reduction  interventions  with  the  goal
of reducing  HCV  transmission  among  PWID.  In evaluating  the  effectiveness  of interventions,  estimates
of HCV  incidence  are  essential.
Methods:  During  2008–2009,  PWID  were  recruited  from  services  providing  sterile  injecting  equipment
across  mainland  Scotland,  completed  an  interviewer-administered  questionnaire  and  provided  a dried
blood spot  for  anonymous  anti-HCV  and  HCV-RNA  testing.  Recent  infections  were  deﬁned  as  anti-HCV
negative  and  HCV-RNA  positive.  Logistic  regression  was  undertaken  to  examine  associations  between
recent  HCV  infection  and  self-reported  uptake  of  methadone  maintenance  therapy  (MMT)  and  injection
equipment.
Results:  Fifty-four  percent  (1367/2555)  of participants  were  anti-HCV  positive.  We  detected  24 recent
HCV  infections,  yielding  incidence  rate  estimates  ranging  from  10.8  to 21.9  per  100 person-years.  After
adjustment  for  confounders,  those  with  high  needle/syringe  coverage  had  reduced  odds  of  recent  infec-
tion (adjusted  odds  ratio  [AOR]  0.32,  95%  CI 0.10–1.00,  p = 0.050).  In the  Greater  Glasgow  &  Clyde  region
only,  we  observed  a  reduced  odds  of  recent  infection  among  those  currently  receiving  MMT,  relative
to  those  on  MMT  in  the  last  six  months  but  not  currently  (AOR  0.04,  95%  CI  0.001–1.07,  p = 0.055).  The
effect  of  combined  uptake  of MMT  and  high  needle/syringe  coverage  was  only  signiﬁcant  in  unadjusted
analyses  (OR  0.34,  95%  CI 0.12–0.97,  p =  0.043;  AOR  0.48,  95%  CI  0.16–1.48,  p =  0.203).
Conclusion:  We  report  the  ﬁrst  large-scale,  national  application  of  a  novel  method  designed to  determine
incidence  of  HCV  among  PWID  using  a cross-sectional  design.  Subsequent  sweeps  of  this  survey  will
increase  statistical  power  and  allow  us  to gauge  the  impact  of  preventive  interventions.
© 2012 Elsevier B.V. All rights reserved.
Introduction
Risk behaviour associated with injecting drug use is the main
mode of transmission of the hepatitis C virus (HCV) in resource-
rich countries. In Scotland, prevalence rates of 21–70% have been
detected among regional populations of people who  inject drugs
(PWID) in recent years (University of the West of Scotland, 2010).
Recognising the importance of tackling the HCV epidemic, the
Scottish Government launched the Hepatitis C Action Plan for Scot-
land, which invested in the development of services to prevent,
∗ Corresponding author. Tel.: +44 141 300 1416; fax: +44 141 300 1170.
E-mail address: norah.palmateer@nhs.net (N.E. Palmateer).
diagnose, treat and care for individuals who  are infected with HCV,
or who are at risk of acquiring HCV infection (Scottish Government,
2008). In relation to prevention, the Action Plan acknowledged:
(i) the need for augmentation of harm reduction interventions
(principally injecting equipment provision (IEP)) to prevent HCV
transmission and (ii) that monitoring of HCV transmission among
PWID is essential to establish the impact of increases/changes in
interventions.
Monitoring of HCV among PWID in Scotland and in other
countries has usually involved measuring the prevalence of HCV
antibodies – an indicator of past infection (Hutchinson et al., 2002;
Roy et al., 2007). Although examining long-term trends in HCV
prevalence can inform on the effectiveness of interventions, mea-
sures of incidence of HCV are much more useful in determining
0955-3959/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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short term impact. The traditional method of measuring incidence
– establishing seroconversion through follow-up and repeat testing
of a cohort of individuals – can be expensive and logistically difﬁ-
cult to undertake. Few measures of HCV incidence among Scottish
PWID have been generated to date, and most have used indirect
methods (Roy et al., 2007).
Although harm reduction interventions for PWID – the foremost
being opioid substitution therapy (OST) and IEP – have been shown
to reduce self-reported injecting risk behaviour, there is a dearth
of evidence with respect to their impact on HCV transmission in
this population group (Palmateer et al., 2010). Rather than being
an indication of the ineffectiveness of these interventions, it has
been suggested that the lack of evidence may  be due to limitations
of studies that have been undertaken to date, such as employing
ecological study designs and using crude measures of intervention
uptake (for example, users vs. non-users of IEP services). Further-
more, few studies have measured the ‘coverage’ or intensity of
interventions (e.g. the amount of injecting equipment distributed)
(Lurie, 1997; Turner et al., 2011; Van Den Berg, Smit, Van Brussel,
Coutinho, & Prins, 2007).
In this paper, we investigate the individual-level associations
between self-reported uptake of harm reduction interventions (IEP
and OST) and incidence of HCV from a national survey of PWID
carried out in Scotland. This study is the ﬁrst large-scale, national
application of a novel method designed to determine incidence of
HCV using a cross-sectional design (Hope et al., 2011; Page-Shafer
et al., 2008).
Methods
Design and setting
The Needle Exchange Surveillance Initiative (NESI) is a volun-
tary anonymous cross-sectional survey of PWID undertaken across
mainland Scotland. Between June 2008 and June 2009, partici-
pants were recruited from 22 agencies and 81 pharmacies that
provide sterile injecting equipment (these sites may  also provide
other harm reduction interventions, such as OST), which comprise
42% of IEP services in Scotland (ISD Scotland, 2010). Within logis-
tical constraints (service manager agreement and a private room
where the interviews could take place), services were selected to
be broadly geographically representative. Eligible individuals had
injected drugs in the past and had not participated in the study
during the current survey year. Current injectors (deﬁned as hav-
ing injected in the last 6 months) were oversampled, if necessary,
so that the proportion of the sample comprised by this group was
at least 75% in each recruitment area. The study received ethical
approval from the West of Scotland Research Ethics Service.
Data collection
Trained interviewers approached potential participants,
explained the study and assessed them for eligibility and willing-
ness to participate; reason for refusal, approximate age and gender
of non-participants was recorded. After obtaining informed con-
sent, the interviewers administered a questionnaire to establish
information about participant demographics, injecting history,
injecting risk behaviour, prison history and uptake of harm reduc-
tion interventions and other health services. Participants were
also asked to provide a blood spot sample for HCV testing, which
was obtained via ﬁngerprick using a single-use disposable lancet.
Individuals who completed the questionnaire were provided with
a £5 voucher. All information collected was anonymous: a partici-
pant’s dried blood spot (DBS) was linked to his/her questionnaire
via a unique study number.
Laboratory testing
DBS were extracted and tested in a modiﬁcation of the Ortho
Save 3.0 EIA (Judd et al., 2003). Samples with optical densities of
<0.4, 0.4–0.79 and ≥0.8 were classiﬁed as negative, weak reactive,
and positive for HCV antibody (anti-HCV), respectively. HCV RNA
testing was  undertaken on anti-HCV negative samples using an
‘in house’ PCR assay: the bioMerieux extraction protocol for DBS
on the Easymag and a real-time PCR (Bennett, Gunson, McAllister,
Cameron, & Carman, 2012). The assay detects to 1000 IU/ml in DBS.
The testing was carried out in pools of ﬁve; samples in positive
pools were then tested individually.
Intervention measures
The harm reduction interventions considered here are IEP and
methadone maintenance therapy (MMT)  (methadone is the most
commonly prescribed opioid substitute in Scotland, accounting for
97% of the respondents who  reported receiving pharmacological
treatment for opioid addiction in the last 6 months in this study).
Variables representing two  types of IEP ‘coverage’ were generated:
needle/syringe (N/S) coverage and non-N/S injecting equipment
coverage were determined by dividing the reported number of
obtained sterile N/S and non-N/S equipment (i.e. spoons, ﬁlters
or water ampoules), respectively, by the self-reported number of
injecting events in the previous six months. The distribution of the
latter variables were examined and, given a very large proportion
of individuals who reported receiving at least one N/S for every
injection (i.e. 100% coverage), it was  suspected that respondents
may  have over-reported the numbers of N/S obtained. The thresh-
old separating high and low N/S coverage was  therefore set at 200%
(i.e. two  needles/syringes for every injection). Since the survey con-
tained no questions to ascertain methadone dosage, individuals
were categorised according to whether they were currently receiv-
ing MMT,  had received MMT  in the last six months (but were not
currently receiving it), or had not received MMT  in the last six
months. A combined measure of intervention coverage was  cre-
ated with categories low, medium and high: the combinations of
N/S coverage and MMT  that were used to create these categories
are listed in Box 1
. Respondents who  were not receiving MMT  and had not injected
in the last six months were excluded.
Statistical analysis
Respondents who participated in the study more than once
(duplicates) were identiﬁed in the database using initials, date of
birth, gender and region of interview: either the ﬁrst interview, or
the interview with valid laboratory results, was retained for analy-
sis. Out of a total of 2749 respondents, we  identiﬁed 115 duplicates
(Fig. 1). Anti-HCV weak reactives (representing only 2.7% of those
with DBS results) were treated as anti-HCV positive.
In the very early stages of HCV infection, individuals have high
levels of viraemia prior to developing antibodies (seroconvert-
ing); this has been referred to as the viraemic pre-seroconversion
window period (Page-Shafer et al., 2008). Recent infections
were therefore deﬁned as individuals who  were anti-HCV neg-
ative and positive for RNA on DBS testing. The following
calculation was  used to generate an estimate of incidence:
I = ((365/T)n)/((N − n) + (365/T)n) where I is the incidence, T is the
estimated duration of the viraemic pre-seroconversion window
period, n is the number of recent infections and N is the number of
susceptibles (i.e. anti-HCV negative individuals) (Hope et al., 2011).
Estimates of the duration of the pre-seroconversion window period
(28–65 days) were obtained from the published literature (Glynn
et al., 2005; Netski et al., 2005; Page-Shafer et al., 2008). We  did not
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Box 1: Categories of N/S coverage and MMT  used to create combined intervention coverage.
N/S coverage
<200% ≥200% Did not inject in last six months
MMT
Currently Medium (n = 267) High (n = 275) High (n = 183)
In  the last six months (not currently) Low (n = 21) Medium (n = 12) High (n = 0)
Not  in the last six months Low (n = 218) Medium (n = 140) Excluded (n = 24)
calculate 95% conﬁdence intervals around the incidence estimates
as the uncertainty in the window period duration generated a wide
range of potential values.
Logistic regression was undertaken to examine associations
between recent HCV infection (i.e. anti-HCV negative and RNA pos-
itive) and self-reported uptake of harm reduction interventions
(MMT  and IEP). The reference group for comparison consisted of
anti-HCV negative, RNA negative individuals. Associations between
other variables and recent HCV infection were also explored. Uni-
variable associations between each variable and recent infection
were examined in turn. Multivariable models were subsequently
built by including known or suspected confounders of the rela-
tionship between MMT/IEP and recent HCV infection; injecting
risk behaviour variables and injecting frequency variables were
not considered because they are on the causal pathway. Where
there was a theoretical reason to suspect potential effect modi-
ﬁcation between two variables, the presence of interactions was
assessed by entering interaction terms into the model individually
and examining the p-values (based on the Wald test), as well as
the effect sizes when the analysis was stratiﬁed by the effect mod-
iﬁer. Additionally, sensitivity analyses were undertaken to assess
the robustness of the ﬁnal model(s) to: (i) excluding unexpected
results (incident infections who reported not injecting in the last
six months) and (ii) restricting to current PWID (i.e. those who had
injected in the last six months). All analyses were undertaken in
SPSS version 14.
Results
A total of 2629 respondents completed the questionnaire; com-
prising 63% of potentially eligible clients that were approached.
Non-participants were slightly younger than participants (mean of
29 vs. 34 years); however, both participants and non-participants
had the same gender distribution (72% male).
Among the 2555 respondents who  provided a sufﬁcient DBS,
1367 (54%) were anti-HCV positive (including weak reactives)
(Fig. 1). Twenty-four of the 1140 anti-HCV negatives (with sufﬁcient
sample) were found to be positive for HCV RNA. This generated
incidence rate estimates ranging from 10.8 to 21.9 per 100 per-
son years, corresponding to viraemic pre-seroconversion window
period estimates of 28–65 days.
In univariable analyses (Table 1), the following variables
were found to be signiﬁcantly associated with increased odds
of recent HCV infection: homelessness in the last six months,
Sample size 2,749
2,555 tested for 
HCV antibody
1,367 (54%) anti-
HCV positivea
1,188 (46%) anti-
HCV negative
1,140 (96%) tested 
for HCV RNA
24 (2%) 
RNA positive
48 insufficient or
inhibitory sample
1,116 (98%) 
RNA negative
115 duplicate interviews
5 incomplete questionnaires
2,629 completed 
questionnaires
74 refused or 
insufficient DBS
Fig. 1. Flowchart of participants through the study. aIncludes weak reactives.
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Table 1
Descriptive characteristics of study sample and univariable logistic regression analyses of associations with recent HCV infection (n = 1140).
No. HCV Ab-ves (N) No. recent infectionsa (n) % (n/N) OR 95% CI p-Value
Gender (5 non-responses)
Male 835 17 2.0 1
Female 300 7 2.3 1.15 0.47–2.80 0.759
Age
16–30  573 17 3.0 1
>30  567 7 1.2 0.41 0.17–0.99 0.048
Region
Greater Glasgow & Clyde 294 5 1.7 1
Elsewhere 846 19 2.2 1.33 0.49–3.59 0.576
Homeless in last 6 months
No 886 10 1.1 1
Yes  254 14 5.5 5.11 2.24–11.65 < 0.001
Prison  (2 non-responses)
Never 641 9 1.4 1
In  the last six months 142 6 4.2 3.1 1.09–8.85 0.035
In  the past but not last six months 355 9 2.5 1.83 0.72–4.64 0.206
Excessive alcohol consumption (last 12 months)b (6 non-responses)
No 863 11 1.3 1
Yes  271 13 4.8 3.9 1.73–8.82 0.001
Time  since onset of injecting (2 non-responses)
<5 years 447 14 3.1 1
≥5  years 691 10 1.4 0.45 0.20–1.03 0.059
Stimulant injection in last 6 months
No 1008 19 1.9 1
Yes 132 5 3.8 2.05 0.75–5.58 0.161
Received MMT
In the last six months (not currently) 33 3 9.1 1
Currently 725 13 1.8 0.18 0.05–0.68 0.011
Not  in the last six months 382 8 2.1 0.21 0.05–0.85 0.028
Needle/syringe coverage (including N/S obtained from IEP services or other people)c,d
<200% 506 16 3.2 1
≥200% 427 4 0.9 0.29 0.10–0.87 0.028
Combined intervention coverage (N/S and MMT)c,e
Low 239 9 3.8 1
Medium 419 8 1.9 0.5 0.19–1.31 0.157
High  458 6 1.3 0.34 0.12–0.97 0.043
Filter  coveragec,d
<200% 804 19 2.4 1
≥200% 129 1 0.8 0.35 0.05–2.65 0.307
Spoon coveragec,d
<200% 811 19 2.3 1
≥200% 122 1 0.8 0.36 0.05–2.70 0.318
IEP, injecting equipment provision; MMT,  methadone maintenance therapy; N/S, needles/syringes; OR, odds ratio.
a Anti-HCV negative and HCV-RNA positive individuals.
b As deﬁned by UK Royal College of Physicians: >14 units/week for women  and >21 units/week for men.
c See methods for deﬁnitions of coverage.
d Among individuals who reported injecting in the last 6 months.
e Excludes 24 respondents who reported not injecting and not receiving MMT  in last six months.
having been in prison in the last six months, and excessive
alcohol consumption. The following factors were signiﬁcantly
associated with reduced odds of recent HCV infection: age >30
years, receipt of prescribed MMT,  ≥200% N/S coverage (where
sterile N/S had been obtained from IEP services or from other
people), and high coverage of combined interventions. Longer
time since onset of injecting (≥5 years) was also associated
with reduced risk and was marginally statistically signiﬁcant
(p = 0.059).
Table 2 presents two alternative adjusted models: (i) with
MMT and IEP entered as separate variables in the model and
(ii) with a combined measure of MMT  and IEP. In model (i),
those who had ≥200% N/S coverage had a nearly 70% reduc-
tion in odds of recent HCV (AOR 0.3, 95% CI 0.1–1.0), relative
to those with <200% coverage, after adjustment for region,
gender, homelessness, imprisonment, time since onset of inject-
ing and excessive alcohol consumption. The results were also
suggestive of reduction in risk among both those on MMT  cur-
rently and not on MMT  in the last six months, relative to
the baseline group of those who had been on MMT  in the
last six months, although neither association was statistically
signiﬁcant.
In model (ii), the reduced risk of recent infection among those
with high coverage, as compared with low coverage, observed in
univariable analysis (OR 0.3, 95% CI 0.1–1.0) was no longer sta-
tistically signiﬁcant after adjustment (AOR 0.5, 95% CI 0.2–1.5,
p = 0.203).
Suspected interactions between variables were investigated and
there was  some evidence that geographical region modiﬁes the
effect of MMT.  Table 3 shows the adjusted odds ratios for MMT,
stratiﬁed by region: in Greater Glasgow & Clyde (GG&C) there was a
marginally signiﬁcant (p = 0.055) reduced odds of recent HCV infec-
tion among those currently on MMT,  relative to those who had been
prescribed MMT  in the last six months but not currently (AOR 0.04,
95% CI 0.001–1.1). This association was not seen in other Scottish
regions.
Sensitivity analyses were undertaken to examine the robustness
of the main effects model (Table 2i), as described in the methods.
The effect sizes were robust to the exclusion of those who had
not injected in the last six months and the four incident infections
who  had not injected in the last six months (data available from
the authors on request). There was a loss of precision; however,
this was  expected due to the corresponding reduction in sample
size.
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Table 2
Multivariable logistic regression models examining the association between recent HCV infection (HCV-antibody negative RNA-positive) and (i) MMT  and N/S coverage as
separate  variables and (ii) combined MMT  and N/S coverage.
Univariable Multivariablea
OR 95% CI p-Value AOR 95% CI p-Value
(n = 1131)Model (i)
Received MMT  In the last six months (not currently) 1 1
Currently 0.18 0.05–0.68 0.011 0.29 0.07–1.19 0.086
Not  in the last six months 0.21 0.05–0.85 0.028 0.28 0.06–1.22 0.089
N/S  coverage (including N/S
obtained from IEP services or other
people)b
<200% 1 1
≥200% 0.29 0.10–0.87 0.028 0.32 0.10–1.00 0.05
Did  not inject in last 6 months 0.6 0.20–1.83 0.372 1.3 0.38–4.43 0.674
(n = 1107)Model (ii)
Combined intervention coverage
(N/S coverage and MMT)b
Low 1 1
Medium 0.5 0.19–1.31 0.157 0.5 0.18–1.35 0.17
High  0.34 0.12–0.97 0.043 0.48 0.16–1.48 0.203
(A)OR, (adjusted) odds ratio; IEP, injecting equipment provision; MMT, methadone maintenance therapy; N/S, needles/syringes.
a Adjusted for region, gender, homelessness, imprisonment, time since onset of injecting, and excessive alcohol consumption.
b See methods for deﬁnitions of coverage.
Discussion
We  estimated an HCV incidence rate of 11–22 per 100 person-
years in this population of Scottish PWID. This is higher than a
recently reported incidence rate of 5.9 per 100 person-years among
a cohort of PWID in Wales (Craine et al., 2009) but lower than rates
(38–47 per 100 person-years) reported in England (Hope et al.,
2011; Judd et al., 2005). These variations may  be attributable to
differences in risk behaviour among regional injecting populations
and/or study designs/recruitment approaches – two  of the latter
studies employed prospective cohort designs, and one recruited
participants using respondent-driven sampling (RDS). Notably, the
RDS study may  have overestimated HCV incidence due to detec-
tion of a transmission cluster; the authors note that exclusion of
this cluster would result in an incidence rate of 18–25 per 100
person-years (Hope et al., 2011). Historically, regional incidence
rate estimates among PWID in Scotland have ranged from 10 to
29 per 100 person-years (McDonald et al., 2012; Roy et al., 2007).
However, whereas the latter estimates were generally conﬁned
geographically, our estimate applies to mainland Scotland.
A subset (Greater Glasgow & Clyde region) of the data pre-
sented here was included in a previous analysis that examined
the effect of harm reduction interventions by pooling data from
UK studies (Turner et al., 2011). Turner et al. demonstrated an
independent effect of N/S provision on incident HCV infection, a
ﬁnding for which our study provides further evidence using data
collected from across mainland Scotland. These studies are the
ﬁrst to observe a signiﬁcant independent association between N/S
provision and recent HCV infection (European Centre for Disease
Prevention & Control, 2011; Palmateer et al., 2010); possible
reasons for this are likely to be the larger sample sizes (for exam-
ple, in comparison to Van Den Berg et al. (2007))  and the use of
more sensitive measures of exposure to N/S provision. Since cross-
sectional studies are generally cheaper and easier to undertake
than prospective cohort studies, our study was able to achieve a
large sample size through the application of a method to deter-
mine incidence using a cross-sectional design (Hope et al., 2011).
Our study is also the ﬁrst, to our knowledge, to look at sterile
needles/syringes obtained from both IEP services and from other
people, which may  have further increased the sensitivity of this
measure of exposure (since people who obtain sufﬁcient sterile
needles/syringes from others may  have otherwise been misclas-
siﬁed as having low coverage and resulted in a dilution of the
exposure-outcome association). This is an important ﬁnding that
suggests secondary distribution may  play a role in preventing HCV
transmission (Bryant & Hopwood, 2009; Lenton, Bevan, & Lamond,
2006).
In contrast to Turner et al., we did not ﬁnd a signiﬁcant inde-
pendent effect of MMT,  nor a signiﬁcant combined intervention
effect, when considering Scotland overall. This could be due to
statistical power: although we had a larger sample size (by approx-
imately 200), we had fewer recent infections in our sample (24
vs. 40). Nevertheless, as demonstrated by Turner et al. and con-
ﬁrmed in our analysis (although we used a different measure of
MMT), current MMT  was associated with reduced odds of recent
HCV infection in the Greater Glasgow & Clyde region. Our ﬁnding
that the reduced odds of those currently receiving MMT,  when com-
pared to those who  had received MMT  in the last six months (but
not currently), suggests that individuals coming off opioid substitu-
tion are at increased risk of HCV infection. This pattern was  not seen
Table 3
Adjusted odds ratios for the association between interventions and recent HCV infection (HCV-antibody negative RNA-positive), stratiﬁed by effect modifying variables
(n  = 1131).
N Recent HCV (n) Recent HCV (%) Multivariablea
AOR 95% CI p-Value
Prescribed MMT  stratiﬁed by Scottish region
GG&C Last six months 9 2 22.2 1
Currently 205 1 0.5 0.04 0.001–1.07 0.055
Not  in the last six months 77 2 2.6 0.16 0.01–2.55 0.193
Other  Scottish regions Last six months 24 1 4.2 1
Currently 515 12 2.3 0.73 0.08–6.64 0.777
Not  in the last six months 301 6 2.0 0.59 0.06–5.67 0.647
AOR, adjusted odds ratio; GG&C, Greater Glasgow & Clyde; MMT,  methadone maintenance therapy.
a Adjusted for gender, homelessness, imprisonment, time since onset of injecting, and excessive alcohol consumption.
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in the other Scottish regions covered by this study: regional vari-
ations in the effectiveness of MMT  may  reﬂect differences in local
delivery policies and practices. However, it is of note that our study
applies the same design and questionnaire across all areas, whereas
the Turner et al. study pooled data from studies which employed a
mixture of different designs (respondent-driven sampling, cohort,
cross-sectional) and questionnaires.
We  did not ﬁnd any signiﬁcant associations between the pro-
vision of ﬁlters or spoons and recent HCV infection: again, this is
possibly attributable to insufﬁcient statistical power. Additionally,
this study was undertaken prior to the substantial changes in IEP
services associated with the Hepatitis C Action Plan in Scotland, one
of which was an approximately ﬁve-fold increase in the provision
of ﬁlters and spoons between 2008/09 and 2009/10 (ISD Scotland,
2011).
Non-intervention variables that were found to be associated
with recent HCV infection in these analyses (age, homeless-
ness, imprisonment) are also consistent with previous studies
(Champion et al., 2004; Craine et al., 2009; Maher et al., 2006;
Thorpe et al., 2002). We  are not aware of any studies that
have found an association between alcohol consumption and
recent/incident HCV infection; however, previous studies have
suggested a link between alcohol consumption and injecting risk
behaviour (Arasteh & Des Jarlais, 2009; Sander, Cole, Ostrow,
Mehta, & Kirk, 2010; Vidal-Trécan et al., 1998). The ﬁnding that
those with shorter injecting histories (<5 years) had a higher odds
of recent HCV infection suggests that interventions targeted at new
initiates to injecting may  be important in reducing HCV incidence.
This study has a number of limitations. Firstly, it was  not specif-
ically designed to examine MMT  as an intervention. We  did not
collect information on methadone dosage from participants and,
furthermore, methadone dosage remains a problematic measure
of methadone coverage since an ‘adequate’ dosage can vary greatly
from person to person.
Selection bias, which has been well documented in other stud-
ies of IEP programmes (Lurie, 1997; Palmateer et al., 2010), may  be
present here. Since recruitment was from sites that provide ster-
ile injecting equipment (some of which will also dispense MMT)
rather than dedicated drug treatment sites, we are more likely to
have sampled individuals who were receiving both MMT  and N/S.
We will also have oversampled those on MMT  who continue to
inject, since we conﬁned the proportion of non-current injectors
(i.e. had not injected in the last 6 months) to 25% of the sam-
ple. We  may  thus have been more likely to sample individuals
receiving inadequate methadone dosages, since such individuals
are likely getting injecting equipment in order to “top up” with
heroin; measures of MMT  effectiveness may  therefore be underes-
timated. Recruitment at solely IEP sites may  also bias the sample
away from high risk injectors who are not in contact with ser-
vices. Previous community-wide surveys undertaken in Glasgow
showed that 90% of PWID recruited from street sites had visited
IEP services in the past six months (Taylor et al., 2000); however,
exclusion of individuals not in contact with services may  still lead
to underestimation of the impact of interventions.
We observed four recent infections among those who reported
not injecting in the last six months. Two of these four individu-
als reported receiving an HCV-positive result from a previous test.
Possible reasons for this discrepancy could be false positive PCR
results or false negative anti-HCV results. It is also plausible that the
respondents were dishonest or incorrectly recalled their behaviour;
however, we cannot conclusively discount other risk factors, such
as tattooing, on which we did not collect information. Self-reported
risk behaviour among PWID may  be subject to social desirabil-
ity or recall biases; however, it is unlikely to differ systematically
between those who received/did not receive interventions or those
with/without the outcome of interest. Respondents may  have
overestimated self-reported uptake of clean needles/syringes but
the effect of this is likely to be non-differential. Thus, the 200%
threshold is not meaningful in itself, except as an indicator of those
with a higher ratio of clean N/S to injections. However, we recognise
that the appropriate ratio of sterile N/S to injections is important
for policy-makers and injecting equipment providers, and therefore
further work is required to elucidate this ratio.
The approach to calculating incidence applied in this study is
heavily dependent on accurate estimation of the duration of the
pre-seroconversion window period, around which there is uncer-
tainty (Glynn et al., 2005; Netski et al., 2005; Page-Shafer et al.,
2008). We  examined intervention uptake in the six months prior
to interview: since this time frame is longer than the upper esti-
mates of the duration of the window period, this may contribute to
some inaccuracy in the results.
The laboratory test to detect antibodies to HCV on DBS has been
validated and has very high sensitivity and speciﬁcity (99% and
100%, respectively) (Judd et al., 2003); the respective values for the
PCR test on DBS are 100% and 96%, (Bennett et al., 2012). Recent
infections could have been missed if the sample was taken dur-
ing a ‘dip’ – a phase of undetectable viral load during a period of
ﬂuctuating viraemia that is observed, in some individuals, in the
acute phase of HCV infection (Thomson, Smith, & Klenerman, 2011).
Conversely, a small proportion of the recent infections might have
been false positives. There is also a chance that chronic infections
could have been misclassiﬁed as recent infections in the case of
immunosuppressed individuals (for example, those infected with
HIV (Thomson et al., 2009)), who may  have delayed seroconversion.
Given the low HIV prevalence in the Scottish injecting population
(Health Protection Scotland & University of the West of Scotland,
2008), we  do not believe this would be a signiﬁcant factor; how-
ever, other lifestyle factors may  contribute to immunosuppression,
including the use of opiates themselves (Vallejo, de Leon-Casasola,
& Benyamin, 2004).
In conclusion, this study utilised a method of generating inci-
dence using a cross-sectional design and demonstrated that high
coverage of N/S is associated with a reduction in recent HCV
infection among PWID in Scotland. Despite the large sample size,
statistical power was nevertheless an issue, since only 24 recent
infections were detected among a sample of more than 1100 HCV
antibody-negatives. Additional sweeps of this survey will increase
the cumulative sample size (and therefore power to detect asso-
ciations) and allow us to examine the impact of the increase in
interventions delivered by the Hepatitis C Action Plan for Scotland.
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